PatternsRadar
Sign in

DIVISLABDivi's Laboratories Limited

NSEF&O
Full chart
9,550.00INR+354.00 (+3.85%)Close · 6 Oct 2026
1 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹2.54L CrMarket cap
86.7P/E (TTM)
63.4%Delivery

Filings & corporate actions

77 results filed
CSV
Next results · Q2 FY27
Expected 6 Nov 2026 – 9 Nov 2026
Estimate: filed 37–40 days after quarter end, last 5 times
Dividend
₹30.00 per share · last 24 Jul 2026
2026
  • 1 AugresultsResults · Q1 FY27 · consolidated and standalone+6.6%NSE
  • 24 JuldividendDividend · ₹30.00 per share-0.8%
  • 17 JulshareholdingShareholding · 30 Jun 2026-0.9%NSE
  • 23 MayresultsResults · Q4 FY26 · consolidated and standalone-1.9%NSE
  • 15 AprshareholdingShareholding · 31 Mar 2026+1.8%NSE
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone+3.4%NSE
  • 9 JanshareholdingShareholding · 31 Dec 2025+0.2%NSE

Reaction to results · all yearsrose on day 0 in 36 of 77 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY271 Aug 2026+6.6%+3.0%+17.5%3.6×
Q4 FY2623 May 2026-1.9%-5.1%-2.0%2.6×
Q3 FY2611 Feb 2026+3.4%+1.7%+1.7%3.6×
Q2 FY267 Nov 2025+0.5%-2.1%-4.9%0.8×
Q1 FY266 Aug 2025-4.3%-4.8%-6.2%3.5×
Q4 FY2517 May 2025+4.8%+7.3%+6.5%4.2×
Q3 FY253 Feb 2025+3.6%+1.1%-6.2%3.2×
Q2 FY259 Nov 2024-0.8%-0.8%-0.4%2.6×
Q1 FY253 Aug 2024-3.3%-2.0%+1.5%2.2×
Q4 FY2425 May 2024+3.2%+4.8%+10.1%5.5×
Q3 FY2410 Feb 2024+2.4%+1.9%-1.3%2.8×
Q2 FY246 Nov 2023-0.7%+0.1%+6.5%3.3×
Q1 FY2414 Aug 2023-0.5%-0.7%+0.5%1.2×
Q4 FY2320 May 2023+5.4%+12.3%+15.7%3.8×
Q3 FY233 Feb 2023-3.7%-3.9%-1.3%4.4×
Q2 FY237 Nov 2022-3.4%-3.7%-2.2%5.4×
Q1 FY2312 Aug 2022+0.2%-5.2%-1.5%2.4×
Q4 FY2223 May 2022-6.1%-7.9%-7.7%10.4×
Q3 FY2211 Feb 2022-0.3%-0.8%+2.2%1.7×
Q2 FY226 Nov 2021-6.0%-5.8%-11.2%6.3×
Q1 FY227 Aug 2021-0.2%-0.3%+6.0%1.9×
Q4 FY2129 May 2021+1.8%+2.7%+4.7%4.9×
Q3 FY216 Feb 2021-1.1%-2.9%-8.2%2.8×
Q2 FY217 Nov 2020+5.8%+5.9%+15.1%6.1×
Q1 FY218 Aug 2020+12.0%+12.4%+14.9%4.3×
Q4 FY206 Jun 2020-1.9%-5.1%-12.2%3.0×
Q3 FY205 Feb 2020+3.1%+9.8%+14.1%4.1×
Q2 FY205 Nov 2019+1.1%-1.8%+6.8%2.4×
Q1 FY2010 Aug 2019-8.4%-7.9%-2.2%5.2×
Q4 FY1925 May 2019-9.8%-8.5%-9.2%6.6×
Q3 FY1918 Feb 2019-2.9%-1.6%+4.6%1.2×
Q2 FY1930 Oct 2018+3.2%+2.6%+1.1%2.9×
Q1 FY1924 Aug 2018+0.5%+0.9%+7.3%0.7×
Q4 FY1821 Jun 2018-2.5%-7.7%-0.4%0.6×
Q3 FY1830 Jan 2018-3.8%-6.2%-5.7%1.4×
Q2 FY182 Nov 2017+16.2%+9.3%+12.7%8.4×
Q1 FY185 Aug 2017+0.3%-6.3%+2.4%0.4×
Q4 FY1730 May 2017+3.2%+10.7%+12.6%2.5×
Q3 FY176 Feb 2017-2.3%-4.1%+2.5%0.5×
Q2 FY1714 Nov 2016-4.9%-3.4%-5.0%2.3×
Q1 FY1727 Sept 2016-0.9%-2.5%-4.2%0.5×
Q4 FY1629 May 2016+2.4%+5.3%+1.2%2.7×
Q3 FY166 Feb 2016-3.8%-10.6%-7.9%1.6×
Q2 FY1631 Oct 2015+0.2%-1.3%-1.4%1.2×
Q1 FY1610 Aug 2015+3.8%+11.1%+1.5%3.2×
Q4 FY1523 May 2015-2.0%-1.4%-2.4%1.9×
Q3 FY1531 Jan 2015-3.0%-7.1%+1.3%3.5×
Q2 FY156 Nov 2014+1.8%+0.2%-1.8%3.3×
Q1 FY1518 Aug 20140.0%+8.0%+14.4%1.0×
Q4 FY1426 May 2014-4.1%-3.8%+4.5%3.6×
Q3 FY144 Feb 2014+2.2%+3.3%+8.7%4.1×
Q2 FY1426 Nov 2013+0.1%-0.9%+3.2%0.9×
Q1 FY145 Aug 2013+2.9%+7.6%+4.9%1.9×
Q4 FY1321 May 2013-7.0%-9.2%-11.1%6.0×
Q3 FY134 Feb 2013-2.1%+0.8%+0.7%1.3×
Q2 FY133 Nov 2012-3.9%-0.4%-2.2%2.2×
Q1 FY136 Aug 2012+0.7%+1.6%+0.4%2.1×
Q4 FY1214 May 2012+7.3%+12.9%+12.0%4.0×
Q3 FY1228 Jan 2012-3.9%-4.0%-11.5%3.1×
Q2 FY121 Nov 2011+0.3%-2.9%+0.4%2.8×
Q1 FY128 Aug 2011-2.3%-7.8%-8.3%1.4×
Q4 FY1126 May 2011-0.8%+6.9%+1.7%2.9×
Q3 FY114 Feb 2011+4.0%+0.6%-2.5%5.1×
Q2 FY119 Nov 2010-2.6%-7.0%-19.2%4.8×
Q1 FY1112 Aug 2010-0.4%-0.3%+2.3%1.0×
Q4 FY1024 May 2010+4.2%+7.7%+11.8%2.5×
Q3 FY1029 Jan 2010+1.1%-6.4%+3.7%0.7×
Q2 FY1030 Oct 2009-2.1%+6.9%+16.4%0.6×
Q1 FY1031 Jul 2009-4.5%-14.7%-1.8%5.4×
Q3 FY0924 Jan 2009-8.6%-5.7%-12.1%4.5×
Q2 FY0929 Oct 2008+13.4%+28.7%+17.8%1.8×
Q1 FY0926 Jul 2008+0.4%+5.1%+4.3%0.6×
Q4 FY089 Jun 2008-2.6%+1.1%-8.8%1.6×
Q3 FY0828 Jan 2008-2.5%-1.3%-8.1%0.6×
Q2 FY0827 Oct 2007+4.8%+1.7%-1.2%1.2×
Q1 FY0830 Jul 2007-1.8%-9.2%-15.5%0.7×
Q4 FY0723 May 2007+16.5%+22.6%+49.6%7.2×
Average+0.2%+0.3%+1.6%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+27.8%
Profit YoY+65.5%
Interest cost YoY+420.0%
Revenue QoQ+8.8%
Profit QoQ+20.1%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+17.1%+15.5%+5.0%+9.3%+11.1%—
Profit+32.2%+25.6%-1.5%+7.4%+10.6%—

Key data

CSV
Open9,210.00
Day range9,165.00 – 9,557.50
52-week range5,636.50 – 9,740.00
From 52w high-2.0%
RSI (14)60.5
ATR (14)211.56
Volume4.65L
Avg volume (20D)5.17L
Rel volume0.90×
Volatility (1Y)24.1%
Turnover₹444.2Cr
SMA 50 / 2008,891.52 / 7,067.09

Delivery percentage

Latest · 6 Oct 202663.4%
20-day avg63.7%
1-year avg56.3%
Percentile (own history)90th
Range11.1–81.9%
Sessions1,731

Over the last 20 sessions DIVISLAB settled 63.7% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 56.3%, so recent sessions are running 7.4 points higher than usual. The latest session ranks higher than 90% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLABZYDUSLIFE

Performance returns

CSV
1D1W1M3M6M1Y
Price+3.85%0.00%+3.24%+41.03%+63.07%+67.85%

Valuation

CSV
Market cap₹2.54L Cr
P/E (TTM)86.7
EPS (TTM)110.18
Shares outstanding26.50Cr
Listed12 Mar 2003

Ownership

CSV
Promoter51.88%
Promoter Δ QoQ0.00 pp
Public48.12%
FII20.20%
DII19.38%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)2,715.02,604.02,831.03,080.0
YoY chg+16.1%+12.3%+9.5%+27.8%
Net profit (₹ Cr)689.0583.0751.0902.0
YoY chg+35.1%-1.0%+13.4%+65.5%
Net margin25.4%22.4%26.5%29.3%
EPS25.9721.9828.3133.95

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 51.88% · public 48.12%
30 Sept 2021: promoter 51.95%31 Dec 2021: promoter 51.95%31 Mar 2022: promoter 51.94%30 Jun 2022: promoter 51.94%30 Sept 2022: promoter 51.94%31 Dec 2022: promoter 51.94%31 Mar 2023: promoter 51.94%30 Jun 2023: promoter 51.93%30 Sept 2023: promoter 51.93%31 Dec 2023: promoter 51.92%31 Mar 2024: promoter 51.92%30 Jun 2024: promoter 51.90%30 Sept 2024: promoter 51.89%31 Dec 2024: promoter 51.89%31 Mar 2025: promoter 51.89%30 Jun 2025: promoter 51.89%30 Sept 2025: promoter 51.89%31 Dec 2025: promoter 51.88%31 Mar 2026: promoter 51.88%30 Jun 2026: promoter 51.88%
2021-092026-06
  • Promoter
  • Public and others
Promoter
51.88%
Public
48.12%
Promoter change
0.00 pp
Filed
17 Jul 2026
FII
20.20%
DII
19.38%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations1,909.01,855.02,303.02,118.02,338.02,319.02,585.02,410.02,715.02,604.02,831.03,080.0
Other income86.095.079.079.0106.082.086.0119.0145.088.0155.064.0
Total income1,995.01,950.02,382.02,197.02,444.02,401.02,671.02,529.02,860.02,692.02,986.03,144.0
Total expenses1,526.01,461.01,669.01,593.01,722.01,675.01,807.01,796.01,948.01,838.02,023.01,964.0
└ Finance costs1.00.02.00.01.00.01.03.08.06.06.06.0
└ Depreciation95.095.095.097.099.099.0107.0112.0113.0118.0120.0133.0
Profit before tax469.0489.0713.0604.0722.0726.0864.0733.0912.0780.0963.01,180.0
Tax expense121.0131.0175.0174.0212.0137.0202.0188.0223.0197.0212.0278.0
Net profit348.0358.0538.0430.0510.0589.0662.0545.0689.0583.0751.0902.0
EPS13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Net margin18.23%19.30%23.36%20.30%21.81%25.40%25.61%22.61%25.38%22.39%26.53%29.29%
PBT margin24.57%26.36%30.96%28.52%30.88%31.31%33.42%30.41%33.59%29.95%34.02%38.31%
Tax rate25.80%26.79%24.54%28.81%29.36%18.87%23.38%25.65%24.45%25.26%22.01%23.56%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 1 Aug 2026.

DIVISLAB at a glance

  • DIVISLAB closed at ₹9,550 on 6 Oct 2026, +3.85% on the day, +67.9% over one year, 2.0% below its 52-week high of ₹9,740.
  • Delivery was 63.4% of traded quantity on 6 Oct 2026, the 90th percentile of its own 1,731 sessions with a reading (20-session average 63.7%, 1-year average 56.3%).
  • Market capitalisation is ₹2.54 lakh crore at a trailing P/E of 86.7 (trailing EPS ₹110.18).
  • Q1 FY27 results (consolidated, filed 1 Aug 2026): revenue ₹3,080 crore (+27.8% year on year), net profit ₹902 crore (+65.5%); the price moved +6.6% on the first session after.
  • Promoters held 51.88% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 6 Nov 2026 and 9 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE361B01024
SeriesEQ
Listed12 Mar 2003
History from12 Mar 2003
Sessions5,852
Turnover rank#42

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE